The safety of supramaximal doses,of candesartan cilexitil (160 mg) in hypertensive subjects with chronic, renal disease.

被引：0
|
作者：
Weinberg, MS
Weinberg, AJ
Zappe, D
Haneiwich, R
Ljunggren, A
机构：
[1] Boston Univ, Affiliated Hosp, Roger Williams Med Ctr, Providence, RI USA
[2] Boston Univ, CAS, Boston, MA 02215 USA
[3] Hypertens & Nephrol Inc, Providence, RI USA
[4] AstraZeneca Pharmaceut Inc, AstraZeneca R&D, Molndal, Sweden
来源：
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2003年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：763A / 763A
页数：1
相关论文
共 13 条
  • [1] The safety and efficacy of supramaximal doses of candesartan cilexetil (160mg) in chronic renal disease patients naive to angiotensin receptor blockade therapy
    Weinberg, AJ
    Haneiwich, R
    Weinberg, MS
    AMERICAN JOURNAL OF HYPERTENSION, 2003, 16 (05) : 103A - 103A
  • [2] The safety of suprmaximal doses of candesartan cilexetil (160mg) in the reduction of proteinuria in chronic renal disease
    Weinberg, A
    Haneiwich, R
    Oza, N
    Weinberg, M
    JOURNAL OF HYPERTENSION, 2003, 21 : S41 - S41
  • [3] Efficacy and safety of valsartan 160/HCTZ 25 mg in fixed combination in hypertensive patients not controlled by candesartan 32 mg plus HCTZ 25 mg in free combination
    Schweizer, J.
    Hilsmann, U.
    Neumann, G.
    Handrock, R.
    Klebs, S.
    CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (11) : 2877 - 2885
  • [4] Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease
    Courtney, R
    Sansone, A
    Smith, W
    Marbury, T
    Statkevich, R
    Martinho, M
    Laughlin, M
    Swan, S
    JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (02): : 185 - 192
  • [5] Evaluation of the efficacy and safety of Diltiazem 300 mg Retard in hypertensive patients with chronic renal failure.
    Bernadet-Monrozies, P
    Poilleux, E
    Suc, JM
    ANNALES DE CARDIOLOGIE ET D ANGEIOLOGIE, 1998, 47 (08): : 589 - 594
  • [6] Relationship between ankle-brachial index and chronic renal disease in hypertensive subjects with no known cardiovascular disease
    Mostaza, J.
    De la Pena, A.
    Gonzalez-Sarmiento, E.
    Vega-Rollan, F.
    Rodilla, E.
    Mangas, A.
    Linares, J.
    Carrasco, F.
    ATHEROSCLEROSIS SUPPLEMENTS, 2007, 8 (01) : 145 - 146
  • [7] Evaluation of 25 OH vitamin D concentrations in samples from subjects with chronic renal failure or end stage renal disease.
    MacFarlane, GD
    Sackrison, JL
    Ersfeld, DL
    Miller, AB
    Bucklen, A
    JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 : S407 - S407
  • [8] BLOOD PRESSURE TARGETS AND MORTALITY IN HYPERTENSIVE PATIENTS WITH CHRONIC RENAL DISEASE. SYSTEMATIC REVIEW AND META-ANALYSIS
    Mendez, Ivan
    Carlos Saiz, Luis
    Leache, Leire
    Gutierrez, Marta
    Ignacio Pijoan, Jose
    Menendez-Orenga, Miguel
    Salzwedel, Douglas M.
    Erviti, Juan
    JOURNAL OF HYPERTENSION, 2022, 40 (SUPPL) : E317 - E317
  • [9] An open study to assess the safety and tolerability of meloxicam 15 mg in subjects with rheumatic disease and mild renal impairment
    Bevis, PJR
    Bird, HA
    Lapham, G
    BRITISH JOURNAL OF RHEUMATOLOGY, 1996, 35 : 56 - 60
  • [10] Estimating glomerular filtration rate in hypertensive subjects: Comparison of the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) Study equations
    Korhonen, Paivi E.
    Kivela, Sirkka-Liisa
    Aarnio, Pertti T.
    Kautiainen, Hannu
    Jarvenpaa, Salme
    Kantola, Ilkka M.
    ANNALS OF MEDICINE, 2012, 44 (05) : 487 - 493
12